psychosociale problemen neuroendocrine tumor/distress quality of life
Conditions
Interventions
Eligible patients will be randomized in two groups. The control group will
receive standard care. In addition to standard care, the experimental group
will be given access to the web-based tailored
information
neuroendocrine tumor
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: • Adult NET patients (aged >= 18 years of age) with any tumor site and disease stage. • Ability to comprehend Dutch (both reading and writing). • Informed consent provided.
Exclusion criteria
Exclusion criteria: • Estimated life expectancy less than 3 months. • Patients who have a history of another primary malignancy, except for radical and adequately treated malignancies from which the patient has been disease free for >= 3 years • Patients who participated in the WIN-pilot study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the difference in distress measured by the distress thermometer and the mean improvement of the global score of the EORTC QLQ-INFO 25 at end of study between the control group and the intervention group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints will be change in quality of life as determined by the cancer-specific EORTC QLQ-C30, and the EORTC QLQ-GINET21, empowerment (subscales of the Construct Empowering Outcomes questionnaire) at end of study, and to have information about patients* opinion and use of the web-based tailored information and support system (using a constructed questionnaire). | — |
Countries
The Netherlands
Outcome results
None listed